Australian biotech market watch 22/01/10
Friday, 22 January, 2010
Health and biotech stocks have followed the All Ordinaries on a slide in morning trading on the back of a weak week in Wall St and concerns over the global economy. The All Ords are down 1.8% in early afternoon trading, with the S&P Health Care index experiencing a slight recovery from this morning, down only 0.25% as of 1pm.
One of the biggest drops was had by Mesoblast (ASX:MSB), which shed 18c to $1.95, although it's still up 44% over the past month.
Sirtex Medical (ASX:SRX) has also dropped 6%, down to $7.07, and Prima BioMed is back to 17c after bumping to 18c at yesterday's close.
pSivida (ASX:PVA) shed 23c, down to $4.05, and Patrys (ASX:PAB) has continued its decline of the past week, down 3.9% to 12.5c.
It wasn't all bad news, though. Cochlear (ASX:COH) managed to put on $1.69, to $66.12, in a strong morning's trading.
Xenotransplantation specialists, Living Cell Technology, has had some ups and downs over the past week, but recovered today to the tune of 2.4%, up to 21c.
CSL (ASX:CSL) was up slightly, adding 8c to $31.15, and ResMed (ASX:RMD) was steady.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
